ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ASND / dividends
BBIO (34) JAZZ (49) SMMT (40) VTRS (57) ⌘ Pro Terminal →

Ascendis Pharma A/S Ordinary Share (ASND) Dividend Safety Gauge & 10-Year DRIP Compounder

$248.98 -0.91% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $248.10

Ascendis Pharma A/S Ordinary Share (ASND) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $16.55B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ASND Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ASND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Ascendis Pharma A/S Ordinary Share (NASDAQ: ASND) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $248.98 (-0.91% 1D, market cap $16.55B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, ASND ranks #80 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ASND compare to BBIO and JAZZ in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ASND carries a Roarable C+ (69/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, BBIO (BridgeBio Pharma Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $14.60B) and JAZZ (Jazz Pharmaceuticals plc (Ireland)) posts a D grade (49/100 RQD, P/E N/A, ROIC -4.7%, cap $14.02B). Among the 5-stock peer group, ASND leads on earnings multiple (32.8x) while ASND leads on capital efficiency (9.9% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ASND?
▼

For Ascendis Pharma A/S Ordinary Share (ASND), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side and Clean SEC annual filing review with no major hidden accounting time-bombs., while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $248.11 (-0.35%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 9.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY • 57.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510069
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B
Cash (12)Whales (15)SEC (16)Macro (14)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+4.9% Base Target
$308 Bull$261 Base$204 Bear
📬 FREE ASND RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ASND)Realized 20D OHLCV Swing Band: ±5%
Deterministic 5-Pillar Attribution (69/100 Composite)
🔍 WHY ASND SCORES 69/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (23% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Whale & Options Positioning+15/20 pts (22% of score)

20D Institutional Volume Accumulation (±5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
61
Grade C$227.00+5.2% Next Q
Q2 (-2Q)
64
Grade C+$238.90+4.5% Next Q
Q3 (-1Q)
66
Grade B-$249.55-0.2% Next Q
Current
69
Grade C+$248.98+2% Hist 90D α
Trajectory: C (61) → C+ (69)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ASND Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 69/100 (C+) score, ASND faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($242.29) or 200D SMA ($238.71) invalidates the momentum regime and cuts Target Base ($261.30) toward Bear Floor ($203.81).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ASND• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ASND Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 69%NO 31%Trade / Inspect Odds →
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 • REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (8.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $22,610

Est. Year-10 Shareholder Yield: $407/yr
$10.8K
Yr 1
$11.8K
Yr 2
$12.8K
Yr 3
$13.9K
Yr 4
$15.0K
Yr 5
$16.3K
Yr 6
$17.7K
Yr 7
$19.2K
Yr 8
$20.8K
Yr 9
$22.6K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Cash-Flow & Quality Compounder Desk

Cash-Fortress Compounders: Auditing Free Cash Flow & Yield Safety in ASND & A-Rated Leaders

  • ✓12-month Bull/Base/Bear fair-value walkthrough on ASND and its top sector peer
  • ✓Top Roarable A-Rated cash compounders with verified executive & 13F accumulation
  • ✓Includes nightly RQD rating-change & forensic signal email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ASND // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +8.86%⚡ TESTING RESISTANCE
2026-11-03O $253.0H $253.0L $249.0C $249.0VOL 386.8K
RES: $254.3SUP: $204.7SMA50: $242.3SMA200: $238.7
$287.6$264.9$242.2$219.5$196.7RES $254.3SUP $204.7$249.02026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ASND Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ASND Butterfly Map → + Track ASND →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
25.3%/yr Implied 5Y Growth

vs. +12.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ASND today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ASND. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ASND today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ASND)

Health Care Rank #80 of 1015 ⚔️ BBIO vs ASND Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ASND vs. BBIO, JAZZ, SMMT, VTRS)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Ascendis Pharma A/S Ordinary Share (ASND) ranks #80 by composite RQD confidence (69/100, grade C+) and #76 by equity capitalization ($16.55B). Within this direct 5-issuer industry benchmark cohort, ASND leads on earnings valuation at 32.8x trailing P/E, while ASND leads on capital efficiency and profitability with 9.9% ROIC and — gross margin. ASND currently leads its immediate peer cohort in composite quantitative strength at 69/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ASND ACTIVE
Ascendis Pharma A/S Ordinary Share
C+ 69/100 32.8x — 9.9% -0.91% $16.55B Benchmark Subject
BBIO
BridgeBio Pharma Inc.
E 34/100 — 95.8% -35.0% +0.06% $14.60B /bbio-vs-asnd →
JAZZ
Jazz Pharmaceuticals plc (Ireland)
D 49/100 — — -4.7% -0.71% $14.02B /jazz-vs-asnd →
SMMT
Summit Therapeutics Inc.
D- 40/100 — — -35.0% -7.67% $12.82B /smmt-vs-asnd →
VTRS
Viatris Inc.
D+ 57/100 — 35.2% -8.1% -1.92% $21.86B /vtrs-vs-asnd →

2. ASND Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Ascendis Pharma A/S Ordinary Share (ASND) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $16.55B, trailing P/E of 32.8x, forward P/E of 27.6x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. ASND Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ASND stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Ascendis Pharma A/S Ordinary Share (NASDAQ: ASND) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $248.98 (-0.91% 1D, market cap $16.55B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, ASND ranks #80 in composite RQD confidence.

How does ASND compare to BBIO and JAZZ in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ASND carries a Roarable C+ (69/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, BBIO (BridgeBio Pharma Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $14.60B) and JAZZ (Jazz Pharmaceuticals plc (Ireland)) posts a D grade (49/100 RQD, P/E N/A, ROIC -4.7%, cap $14.02B). Among the 5-stock peer group, ASND leads on earnings multiple (32.8x) while ASND leads on capital efficiency (9.9% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ASND?

For Ascendis Pharma A/S Ordinary Share (ASND), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side and Clean SEC annual filing review with no major hidden accounting time-bombs., while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ASND trading relative to its 50-day, 200-day, and 52-week technical levels?

ASND last traded at $248.98 (-0.91% on volume of 480,041 shares), positioning the stock +2.76% above its 50-day simple moving average ($242.29) and +4.30% above its 200-day simple moving average ($238.71). Across its 52-week range of $188.07 to $282.15, ASND sits at the 64.7% percentile with a 14-day RSI of 63.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±5.0% ($236.53 to $261.43).

Direct Sub-Reports: ASND RQD Cockpit ASND 12M Forecast ASND Earnings & Move ASND Dividends & DRIP ASND Insiders & 13F ASND Whale Options ASND Profit Sankey ASND News & Why
ROARABLE RATING BRIEF • RQD 69/100 (C+) ✓ SEC XBRL & RQD VERIFIED

ASND — Ascendis Pharma A/S Ordinary Share: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

Ascendis Pharma A/S Ordinary Share (ASND) earns a live Roarable RQD composite score of 69/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $248.98 (-0.91% 1D, market capitalization $16.55B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 9.9%, gross margin of —, operating margin of 13.9%, and free cash flow yield of 2.21%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (14/20) + Forensic Balance Sheet (16/20): Incorporates a 0.98x equity beta, Altman Z-Score of 3.74, Piotroski F-Score of 8/9, and Debt/Equity of 0.39x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Ascendis Pharma A/S Ordinary Share (ASND) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Per the market data, operating margin is 13.9% and net margin is 10.9%.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 69/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $188.07 – $282.15 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 32.8x trailing P/E and 21.0x EV/EBITDA against 13.9% operating margins and a 0.98x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ASND carries a macro regime beta of 0.98 and gross margin of —.

  • Key Question #1: Can ASND sustain or expand its 13.9% operating margin and 9.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (2.21% FCF yield) strengthen balance-sheet liquidity (Altman Z-Score 3.74) toward the $282.15 52-week high?
  • Key Question #3: How sensitive is ASND's 27.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.98x)?

ASND Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Ascendis Pharma A/S Ordinary Share (ASND) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ASND Debate Forum (3) ↓
🔴 RISK WATCH Benzinga • 18d ago
Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasia

Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization

Read Full Source ↗
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ASND Bull vs. Bear Conversation Board — What's Your Call at $248.98?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ASND 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ASND:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $299.01 (+19.0%)
📌 Pinned Debate

Balance-sheet strength (Altman Z 3.74, Piotroski F 8/9, Debt/Equity 0.39) scores 16/20 on the Roarable RQD rating, the highest of its f

Don't sleep on ASND's setup in Health Care. Balance-sheet strength (Altman Z 3.74, Piotroski F 8/9, Debt/Equity 0.39) scores 16/20 on the Roarable RQD rating, the highest of its five pillars.. Beta of 0.98 means it moves fast when momentum turns, and the 5-pillar RQD gauge (69/100) backs up the fundamental quality.

RetailWhale_TX 🐂 BULL

@RiskArb_Desk Shorting a 15/20 institutional whale-flow stock at $251.27 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $211.07 (-16.0%)
Spot @ $251.27

Per the market data, the stock trades at a trailing P/E of 32.8 and FCF yield of only 2.21%, leaving valuation vulnerable if earnings d

Here is the bear case nobody on the bull side wants to address on ASND: Per the market data, the stock trades at a trailing P/E of 32.8 and FCF yield of only 2.21%, leaving valuation vulnerable if earnings disappoint.. At 32.8x trailing P/E, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%